Poland· PL-100129297
Estazolam Polfarmex
A estazolam product containing estazolamum, registered in Poland by Polfarmex S.A.. The same ATC class is registered in 4 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Estazolam is registered in 4 of 19 countries.
Countries holding a registration under ATC N05CD04 (estazolam), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Estazolam · ATC N05CD04
4 / 19 countries
- Franceprice
- Japan
- Polandprice
- United Statesprice
Price per daily dose
What a daily dose of estazolam costs, country by country.
Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Estazolam · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- FR France$0.15
The record
At a glance
URPL (Poland)- Active substance
- Estazolamum
- Manufacturer
- Polfarmex S.A.
- Country
- Poland (PL)
- ATC code
- N05CD04
- ATC class
- Estazolam
- Defined daily dose
- 3 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909991098339
- gtin05909991098315
- gtin05909991098322
- gtin05909991280260
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
178 interactions on record for estazolam.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Estazolam · interactions on record
178 records
- 4 severe
- 99 moderate
- 22 minor
- 53 info
Most severe, free to view
- MorphineN02AA01severe
- MorphinN07BC09severe
- HydrocodoneR05DA03severe
- CodeineR05DA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Estazolam in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesEstazolamActavis Pharma, Inc.
- FranceNUCTALON 2 mg, compriméCHEPLAPHARM ARZNEIMITTEL (ALLEMAGNE)
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- France · Nuctalon
- Italy · Esilgan
- Lithuania · Estazolam Tc
- Portugal · Kainever
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b2e10ff1-49d7-4d98-b1b9-bb7276278bae GET /v1/drugs/b2e10ff1-49d7-4d98-b1b9-bb7276278bae?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "2 mg",
"packaging": "05909991098315 ¦ Rp ¦ 24731\n20 tabl. w blistrach (2 x 10)\n05909991098322 ¦ Rp ¦ 24732\n20 tabl. w blistrze (1 x 20)\n05909991098339 ¦ Rp ¦ Skasowane ¦ 24733\n20 tabl. w pojemniku\n05909991280260 ¦ Rp ¦ 116263\n28 tabl.",
"substance": "Estazolamum 2 mg",
"common_name": "Estazolamum",
"pl_product_id": "100129297",
"pozwolenie_nr": "10983",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about estazolam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.